Compound Evidence File
#EC-2026-0638
TB-500
Filed under Peptides. The bureau holds 150 laboratory returns for this compound from 37 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
37 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 7 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 8 Dec 2025 | 1 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 9.9 | 10.0 | 2 Feb 2026 | 18 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 10.0 | 10.0 | 19 Jan 2026 | 15 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 10.0 | 9.9 | 10.0 | 15 Feb 2026 | 17 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 13 Mar 2026 | 16 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 10.0 | 10.0 | 4 Jan 2026 | 8 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Apr 2026 | 9 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 18 Dec 2025 | 19 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 10 Apr 2026 | 2 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 9.9 | 10.0 | 4 Mar 2026 | 27 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 9.9 | 10.0 | 25 Apr 2026 | 17 May 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Feb 2026 | 24 Apr 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Apr 2026 | 12 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 23 Jan 2026 | 4 Mar 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 9 Apr 2026 | 10 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 10.0 | 10.0 | 10.0 | 12 May 2026 | 12 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 10.0 | 10.0 | 10.0 | 15 May 2026 | 13 Jun 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 9 Jan 2026 | 1 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 8 Mar 2026 | 12 Apr 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 10.0 | 1 Aug 2026 | 4 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 23 Mar 2026 | 15 May 2026 |
| Xingruida XDRCASE #VI-2026-0898 | X | 1 | 9.4 | 9.4 | 9.4 | 25 May 2026 | 25 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 9.2 | 7.7 | 10.0 | 24 May 2026 | 24 May 2026 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 8.8 | 8.8 | 8.8 | 25 May 2026 | 25 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.4 | 7.2 | 10.0 | 25 May 2026 | 25 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 8 | 8.3 | 7.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | A | 7 | 8.2 | 6.5 | 10.0 | 30 Jan 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 8.2 | 7.8 | 8.7 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 7.9 | 6.7 | 9.8 | 23 May 2026 | 23 May 2026 |
| YimeiCASE #VI-2026-0081 | X | 1 | 7.7 | 7.7 | 7.7 | 25 May 2026 | 25 May 2026 |
| Reta-PeptideCASE #VI-2026-0756 | E | 7 | 6.9 | 2.7 | 9.6 | 24 Jul 2025 | 24 May 2026 |
| LiliPeptideCASE #VI-2026-0695 | D | 6 | 6.3 | 3.6 | 9.2 | 9 Sep 2025 | 18 May 2026 |
| SRY LabsCASE #VI-2026-0657 | E | 8 | 5.0 | 2.7 | 6.8 | 16 May 2025 | 30 Jan 2026 |
| ZLZ PeptideCASE #VI-2026-0524 | E | 4 | 4.9 | 3.0 | 7.8 | 9 Oct 2025 | 29 Dec 2025 |
| Qing Li PeptideCASE #VI-2026-0469 | E | 13 | 4.5 | 0.0 | 8.3 | 29 Jun 2025 | 17 May 2026 |
Open any subject to view the batch-level evidence for TB-500 alone.